Occudo Quantitative Strategies LP Protagonist Therapeutics, Inc Transaction History

Occudo Quantitative Strategies LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$7.36 - $11.17 $78,671 - $119,396	-10,689 Reduced 51.18%	10,198 $111,000
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $923,612 - $1.38 Million	-117,508 Reduced 84.91%	20,887 $176,000
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $812,147 - $2.94 Million	115,035 Added 492.44%	138,395 $1.1 Million
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $545,222 - $842,828	23,360 New	23,360 $553,000
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $420,933 - $885,799	-23,876 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $309,194 - $1.19 Million	23,876 New	23,876 $423,000

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Occudo Quantitative Strategies LP, based on Form 13F filings with the SEC.

Stay updated on Occudo Quantitative Strategies LP with notifications on news.